Matches in Wikidata for { <http://www.wikidata.org/entity/Q90971559> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q90971559 description "article scientifique publié en 2018" @default.
- Q90971559 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q90971559 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90971559 description "scientific article published on 15 August 2018" @default.
- Q90971559 description "wetenschappelijk artikel" @default.
- Q90971559 description "наукова стаття, опублікована в серпні 2018" @default.
- Q90971559 name "Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?" @default.
- Q90971559 name "Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?" @default.
- Q90971559 type Item @default.
- Q90971559 label "Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?" @default.
- Q90971559 label "Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?" @default.
- Q90971559 prefLabel "Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?" @default.
- Q90971559 prefLabel "Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?" @default.
- Q90971559 P1433 Q90971559-6A4E1116-2D6C-4487-8419-360D77C780AF @default.
- Q90971559 P1476 Q90971559-057B040E-4578-4011-8407-6BCF01024C21 @default.
- Q90971559 P2093 Q90971559-286FD6CB-1831-4B40-8578-05E694FB5C0C @default.
- Q90971559 P2093 Q90971559-6A2471FB-4C88-4109-A635-16CC1A52F910 @default.
- Q90971559 P2093 Q90971559-72EA6AB9-0F91-412A-B470-E0864F7B2EEE @default.
- Q90971559 P2093 Q90971559-BD896F14-10DC-4F4E-8841-E85E3BFD0B60 @default.
- Q90971559 P304 Q90971559-596441E1-AAAA-41E9-8DDF-025819CD7E25 @default.
- Q90971559 P31 Q90971559-9CA321C4-36CD-4398-9D2C-B2ABF8B91227 @default.
- Q90971559 P356 Q90971559-9E5630F7-C101-4B45-A12C-5E30DD94CE54 @default.
- Q90971559 P433 Q90971559-60399AE9-5720-418A-B8C2-1999689FF760 @default.
- Q90971559 P478 Q90971559-19B4BB24-410B-46B4-B600-60E8DD16DF18 @default.
- Q90971559 P577 Q90971559-722AF02C-20CA-468E-93A2-CBA969D8CE89 @default.
- Q90971559 P698 Q90971559-DACA6C48-A1EB-44A2-8613-BB45C49829D5 @default.
- Q90971559 P921 Q90971559-9C701298-B86D-41D7-9EAA-2DCE7792F21B @default.
- Q90971559 P356 IJU.13764 @default.
- Q90971559 P698 30112772 @default.
- Q90971559 P1433 Q15767019 @default.
- Q90971559 P1476 "Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?" @default.
- Q90971559 P2093 "Hakujyu Tajima" @default.
- Q90971559 P2093 "Shunya Ikeda" @default.
- Q90971559 P2093 "Tomonori Yamanishi" @default.
- Q90971559 P2093 "Yuriko Yamanishi" @default.
- Q90971559 P304 "863-870" @default.
- Q90971559 P31 Q13442814 @default.
- Q90971559 P356 "10.1111/IJU.13764" @default.
- Q90971559 P433 "10" @default.
- Q90971559 P478 "25" @default.
- Q90971559 P577 "2018-08-15T00:00:00Z" @default.
- Q90971559 P698 "30112772" @default.
- Q90971559 P921 Q17 @default.